Hormone Therapy News

Menarche after the age of 14 years, or going through menopause before 45 years of age, are among the hormonal and reproductive factors that increase the risk for rheumatoid arthritis, according to data published in RMD Open.

According to published results, recombinant human growth hormone therapy was associated with increased risk for proximal tibial physeal avulsion fractures in pediatric patients.

Statin therapy could lower the odds of blood clot formation conferred by hormone therapy in perimenopausal women, according to a case-control study published in JAMA Network Open.

A once-weekly human growth hormone therapy conferred a greater reduction in trunk fat mass and a greater increase in total body lean mass than placebo, according to topline results from a phase 3 trial.

For women experiencing disruptive, bothersome hot flashes, the use of menopausal hormone therapy — a one-time standard but later feared treatment option — is far from straightforward.

Fewer than 1% of adults receiving exogenous testosterone for gender-confirming hormone therapy have a hematocrit level above the norm of 54%, according to data published in The Journal of Clinical Endocrinology & Metabolism.

Transgender and gender-expansive young people report worse quality of life mental health scores compared with the general U.S. population, according to study data.

PHILADELPHIA — In this Healio video exclusive, Leslie Cho, MD, discusses how to assess CV risk when considering use of hormone therapy for bothersome menopausal symptoms.

Testosterone use among transgender men and gender-diverse people was linked to higher interest in sexual activity and also pain or discomfort during sexual activity, researchers reported.

Transgender people who use gender-confirming hormone therapy long term have increases in bone mineral density back to levels observed before pubertal suppression, according to findings published in JAMA Pediatrics.